• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $2,978 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-124 Mln

Dicerna Pharmaceuticals Inc (DRNA) Share Price

$38.22

As on 29-Dec-2021 EST

$0.000.00%

  • Prev Close info

    $38.22

  • Day's Openinfo

    $38.22

  • Today's Highinfo

    $38.22

  • Today's Lowinfo

    $38.22

  • Today's Volumeinfo

    0

  • 52 Week rangeinfo

    $-- - --

Please wait...

Dicerna Pharmaceuticals Inc (DRNA) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Dicerna Pharmaceuticals Inc (DRNA)
73.49 0.61 90.53 71.54 53.15 66.02 --
S&P BSE Sensex*
2.17 3.02 9.37 24.23 13.97 15.40 13.33
#
-- -- -- -- -- -- --
As on 29-Dec-2021  |  *As on 02-Mar-2024  |  #As on
2021
2020
2019
2018
2017
2016
2015
Dicerna Pharmaceuticals Inc (DRNA)
73.49 0.00 106.08 18.27 213.54 -75.74 -27.93
S&P BSE Sensex
21.99 15.75 14.38 5.87 27.91 1.95 -5.03
S&P BSE Sensex
21.99 15.75 14.38 5.87 27.91 1.95 -5.03

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Dicerna Pharmaceuticals Inc (DRNA) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Dicerna Pharmaceuticals Inc (DRNA)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Dicerna Pharmaceuticals Inc (DRNA)

        Co-Founder, CEO, Pres & Director

        Dr. Douglas M. Fambrough III

        Chief Financial Officer

        Mr. Douglas W. Pagan

        Headquarters

        Lexington, MA

        FAQs for Dicerna Pharmaceuticals Inc (DRNA)

        The total asset value of Dicerna Pharmaceuticals Inc (DRNA) stood at $ 1,011 Mln as on 30-Sep-21

        The share price of Dicerna Pharmaceuticals Inc (DRNA) is $38.22 (NASDAQ) as of 29-Dec-2021 EST. Dicerna Pharmaceuticals Inc (DRNA) has given a return of 53.15% in the last 3 years.

        Dicerna Pharmaceuticals Inc (DRNA) has a market capitalisation of $ 2,978 Mln as on 29-Dec-2021. As per Value Research classification, it is a company.

        The P/B ratio of Dicerna Pharmaceuticals Inc (DRNA) is 27.66 times as on 29-Dec-2021, a 8.28% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Dicerna Pharmaceuticals Inc (DRNA) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Dicerna Pharmaceuticals Inc (DRNA) and enter the required number of quantities and click on buy to purchase the shares of Dicerna Pharmaceuticals Inc (DRNA).

        Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.

        The CEO & director of Dr. Douglas M. Fambrough III. is Dicerna Pharmaceuticals Inc (DRNA), and CFO & Sr. VP is Mr. Douglas W. Pagan.

        The promoters of Dicerna Pharmaceuticals Inc (DRNA) have pledged 0% of the total equity as on Nov-21.

        Dicerna Pharmaceuticals Inc (DRNA) Ratios
        Return on equity(%)
        -106.33
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Dicerna Pharmaceuticals Inc (DRNA) was $-124 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $2,977.70 Mln
        • Revenue (TTM)revenue-information $192.85 Mln
        • Earnings (TTM) earning-information $-124.44 Mln
        • Cash date-information $565.51 Mln
        • Total Debt info $64.42 Mln
        • Insider's Holding 7.43%
        • Liquidity liquidity
        • 52 Week range week-range $-- - --
        • Shares outstanding share-outstanding 77,909,504
        • 10 Years Aggregate:

          CFO: $-20.47 Mln

          EBITDA: $-574.61 Mln

          Net Profit: $-589.59 Mln

        About The Company

        • IPO Date 30-Jan-2014
        • Co-Founder, CEO, Pres & Director Dr. Douglas M. Fambrough III
        • Chief Financial Officer Mr. Douglas W. Pagan
        • Listing key-listing NASDAQ: DRNA
        • Country United States
        • Headquarters headquarters Lexington, MA
        • Website website https://dicerna.com
        • Business

          Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform...  for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.  Read more

        share-fund-plan-icon